Hepatitis C virus (HCV)-induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a p
A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C
✍ Scribed by Carlos Margarit; Itxarone Bilbao; Lluis Castells; Iñigo Lopez; Leonor Pou; Elena Allende; Alfredo Escartin
- Book ID
- 110916584
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 137 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0934-0874
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Less potent immunosuppression is considered to reduce the severity of hepatitis C virus (HCV) recurrence after liver transplantation. An optimal regimen is unknown. We evaluated tacrolimus monotherapy versus triple therapy in a randomized trial of 103 first transplants for HCV cirrhosis. One hundred
We read with interest the article by Manousou and colleagues, 1 investigating the impact of tacrolimus monotherapy (MT) versus triple therapy (TT) on recurrent hepatitis C infection after liver transplantation. This study examined hepatic fibrosis progression in patients randomized to tacrolimus MT
The purpose of this study was to evaluate the influence of a steroid-free immunosuppression on hepatitis C virus (HCV) recurrence. A total of 198 liver transplantation (LT) patients were randomized to receive immunosuppression with basiliximab and cyclosporine, either with prednisone (steroid [St] g
For complete listing of investigators and centers, see